<DOC>
	<DOCNO>NCT00818948</DOCNO>
	<brief_summary>This 2-part , multi-center , randomize , double-blind , placebo-controlled , multiple dose escalation study , enrol approximately 48 subject . Part A study enroll subject Systemic Lupus Erythematosus ( SLE ) without Glomerulonephritis ( GN ) 3 cohort . Part B study enroll SLE subject GN 3 cohort . The purpose study evaluate multiple dose AMG 811 safety . Tolerability pharmacokinetics .</brief_summary>
	<brief_title>Safety Study AMG 811 Subjects With Systemic Lupus Erythematosus With Without Glomerulonephritis</brief_title>
	<detailed_description>Part A study enroll SLE without GN ( non-renal ) subject 3 cohort ( 6 AMG 811 : 2 placebo ) . All subject receive dose AMG 811 placebo every 4 week begin Day 1 ( D1 ) total 3 injection . Subjects follow study day 197 , 5 month last dose study medication . Part B study enroll SLE subject GN Cohorts 4 , 5 , 6 ( 6 AMG 811 : 2 placebo ) . Similar Part A , subject Cohorts 4 , 5 , 6 dose every 4 week AMG 811 placebo total 3 injection follow 5 month follow-up period . For Cohort 6 , subject follow 6 month follow-up period .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<criteria>Men woman , age 18 70 year age ; Body mass index 18 40 kg/m2 [ Body Weight ( kg ) /Height2 ( m2 ) ] screen ; Diagnosis SLE least 6 month randomization , include positive antinuclear antibody ( ANA ) screening ; screen ANA negative , documented historical ANA titer least 1:80 acceptable ; Any concurrent SLE pharmacologic regimen ( include mycophenolate mofetil , azathioprine , leflunomide , methotrexate , antimalarial ) must stable least 30 day randomization ; Prednisone ≤ 20 mg/day ( equivalent ) permit ; one increase one decrease ≤ 5 mg/day prednisone equivalent allow within 30 day randomization ; Additional inclusion criterion Part B : Active SLE GN apparent cause , define follow : Renal biopsy evidence ( within 18 month ) nephritis use WHO International Society Nephrology ( ISN ) /Renal Pathology Society ( RPS ) classification SLE GN ( Class III IV ) ; Urine protein/creatinine ratio ( UP/Cr ) &gt; 1 24 hour urine protein &gt; 1g least 12 week treatment mycophenolate mofetil ( least 1.5 grams/day ) azathioprine ( least 100 mg orally per day ) ; Superimposed membranous change allow Class III Class IV SLE GN ; Prednisone ≤ 20 mg/day ( equivalent ) time randomization . Any disorder ( include psychiatric ) , condition clinically significant disease ( diagnosis SLE ) would , progressive nature and/or severity , interfere study evaluation , completion and/or procedure per investigator 's discretion ; Creatinine clearance within screen period le 50 mL/min calculate CockcroftGault method Signs symptoms viral , bacterial fungal infection within 30 day study randomization , recent history repeat infection ; Underlying condition SLE allow immunosuppressant predispose one infection Prior use follow agent : Administration investigational biologic agent primarily target immune system Administration cyclosporine , tacrolimus , sirolimus , IV immunoglobulin , and/or plasmapheresis within 3 month randomization ; Administration oral IV cyclophosphamide ( alkylating agent ) within 12 month ( Part A ) 3 month ( Part B ) randomization ; History ethanol drug abuse within last one year prior randomization ; Additional exclusion criterion Part B : Rapidly progressive GN ( define double serum creatinine within past 3 month ) ; Evidence significant chronicity , define : &gt; 50 % glomeruli sclerosis &gt; 50 % interstitial fibrosis renal biopsy ; International Society Nephrology ( ISN ) /Renal Pathology Society ( RPS ) 2003 Class III ( C ) , IVS ( C ) IVG ( C ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Nephritis</keyword>
</DOC>